Upadacitinib in Action: Efficacy and Safety in the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis

This review examines the efficacy, safety, and pharmacokinetics of upadacitinib (UPA) in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). The review analyzes the results of multiple clinical trials and provides a comprehensive overview of UPA's effectiveness in improving disease activity, reducing symptoms, and preventing joint damage. The review also highlights the safety profile of UPA, including the increased risk of herpes zoster, non-melanoma skin cancer, and elevated creatine phosphokinase levels. Additionally, the review discusses the pharmacokinetics of UPA, emphasizing its rapid absorption and limited plasma protein binding. Overall, UPA appears to be a promising therapeutic option for patients with RA, PsA, and axSpA, particularly those with inadequate response to other therapies.